Cambridge Investment Research Advisors
TARS icon

Cambridge Investment Research Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$898K Buy
14,275
+1,506
+12% +$96.2K ﹤0.01% 2410
2026
Q1 		$896K Sell
12,769
-2,406
-16% -$168K ﹤0.01% 2270
2025
Q4 		$1.24M Buy
15,175
+125
+0.8% +$9.33K ﹤0.01% 1923
2025
Q3 		$894K Sell
15,050
-2,300
-13% -$113K ﹤0.01% 2136
2025
Q2 		$703K Sell
17,350
-5,800
-25% -$261K ﹤0.01% 2234
2025
Q1 		$1.19M Sell
23,150
-25
-0.1% -$1.24K ﹤0.01% 1723
2024
Q4 		$1.28M Sell
23,175
-1,900
-8% -$86.3K ﹤0.01% 1671
2024
Q3 		$825K Buy
25,075
+2,100
+9% +$59K ﹤0.01% 2009
2024
Q2 		$624K Sell
22,975
-1,675
-7% -$56.3K ﹤0.01% 2115
2024
Q1 		$896K Buy
24,650
+3,700
+18% +$109K ﹤0.01% 1805
2023
Q4 		$424K Buy
20,950
+200
+1% +$3.34K ﹤0.01% 2327
2023
Q3 		$369K Buy
+20,750
New +$367K ﹤0.01% 2339

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cambridge Investment Research Advisors's TARS Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 12% in Q2 2026, buying an estimated $96.2K and bringing the position to 14,275 shares worth $898K. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Cambridge Investment Research Advisors first reported a position in TARS in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.28M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Cambridge Investment Research Advisors held 14,275 shares of Tarsus Pharmaceuticals worth $898K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 1,506 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $96.2K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2410 holding.
  • Cambridge Investment Research Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Cambridge Investment Research Advisors's Tarsus Pharmaceuticals position peaked at $1.28M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.